InvestorsHub Logo
Followers 20
Posts 959
Boards Moderated 0
Alias Born 07/08/2013

Re: Hannibal Smith post# 13539

Wednesday, 07/24/2013 8:58:08 AM

Wednesday, July 24, 2013 8:58:08 AM

Post# of 91007
While I cannot discount this argument I have a different take.

Given the enormous profit potential ahead, selling the company in the near-term does not benefit those who have been involved for as long as they have. It would no longer benefit those big names who have signed on as members of the board or as advisors.

Another reason I think they may not sell (at least right away) is opportunity to make history. Fame, money and power are huge motivators. If they sold out to Big Pharma any future developments benefit the acquiring company and not those who made it happen (e.g. those who have been involved with the company through thick and thin). It's not that they won't have jobs necessarily so it has to do with the pride, prestige and money that would come from building a company from nothing into the next multi-billion dollar biotech. Scientists and doctors want to leave their legacy and imprint on history and selling the company diminishes those possibilities greatly.

I would hope that the more interest Big Pharma showed the more hesitant the company would be to sell. If for no other reason than to sell now or short term would be selling way too low.

Of course anything can be negotiated so a deal could be worked out that sweetens the deal for Victor and others.

And yes, I would absolutely prefer they do not sell the company until the PPS were in the tens of dollars if they were thinking about selling it. Should a buy out offer come to light there could be a bidding war amongst the biggies especially if it is sooner than later because the cost to the acquirer would be relatively small given the potential.

Regardless of what happens I think it's all positive for PPS appreciation.

Have a great day folks!

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.